Company profile LCTX

Lineage Cell Therapeutics Inc
biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells ha...ve potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products. Show More
Quarter analysis & expected interest

There is not enough data for Lineage Cell Therapeutics near me to provide analysis

Correlation between past revenue and Lineage Cell Therapeutics near me search interest

There is not enough data for Lineage Cell Therapeutics near me to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lineage Cell Therapeutics near me to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 01:23:42.

After 38 days of this quarter the interest is at 93.0. Based on that we can calculate that during remaining 53 days it will total up to 223.0.
Lineage Cell Therapeutics stock expected interest is significantly higher compared to previous quarter (+1138.9%) and same quarter last year (+197.3%).

YearQ1Q2Q3Q4
201922
127
477.3% QoQ
126
-0.8% QoQ
28
-77.8% QoQ
2020 64
190.9% YoY 128.6% QoQ
26
-79.5% YoY -59.4% QoQ
60
-52.4% YoY 130.8% QoQ
25
-10.7% YoY -58.3% QoQ
2021 146
128.1% YoY 484.0% QoQ
37
42.3% YoY -74.7% QoQ
222
270.0% YoY 500.0% QoQ
151
504.0% YoY -32.0% QoQ
2022 154
5.5% YoY 2.0% QoQ
49
32.4% YoY -68.2% QoQ
84
-62.2% YoY 71.4% QoQ
77
-49.0% YoY -8.3% QoQ
2023 75
-51.3% YoY -2.6% QoQ
34
-30.6% YoY -54.7% QoQ
88
4.8% YoY 158.8% QoQ
18
-76.6% YoY -79.5% QoQ
2024 93
24.0% YoY 416.7% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Lineage Cell Therapeutics stock search interestLast update: February 08 2024 01:23:42.
Correlation coefficient between keyword and revenue is 0.19
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 01:23:42.

The average 5 years interest of Lineage Cell Therapeutics stock was 6.54 per week.
The last year interest of Lineage Cell Therapeutics stock compared to the last 5 years has changed by -15.29%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -9.62%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lineage Cell Therapeutics company news to provide analysis

Correlation between past revenue and Lineage Cell Therapeutics company news search interest

There is not enough data for Lineage Cell Therapeutics company news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lineage Cell Therapeutics company news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lineage Cell Therapeutics clinical trials to provide analysis

Correlation between past revenue and Lineage Cell Therapeutics clinical trials search interest

There is not enough data for Lineage Cell Therapeutics clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lineage Cell Therapeutics clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lineage Cell Therapeutics cell therapy to provide analysis

Correlation between past revenue and Lineage Cell Therapeutics cell therapy search interest

There is not enough data for Lineage Cell Therapeutics cell therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lineage Cell Therapeutics cell therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lineage Cell Therapeutics degenerative diseases to provide analysis

Correlation between past revenue and Lineage Cell Therapeutics degenerative diseases search interest

There is not enough data for Lineage Cell Therapeutics degenerative diseases to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lineage Cell Therapeutics degenerative diseases to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lineage Cell Therapeutics OpRegen to provide analysis

Correlation between past revenue and Lineage Cell Therapeutics OpRegen search interest

There is not enough data for Lineage Cell Therapeutics OpRegen to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lineage Cell Therapeutics OpRegen to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lineage Cell Therapeutics OPC1 to provide analysis

Correlation between past revenue and Lineage Cell Therapeutics OPC1 search interest

There is not enough data for Lineage Cell Therapeutics OPC1 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lineage Cell Therapeutics OPC1 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lineage Cell Therapeutics VAC2 to provide analysis

Correlation between past revenue and Lineage Cell Therapeutics VAC2 search interest

There is not enough data for Lineage Cell Therapeutics VAC2 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lineage Cell Therapeutics VAC2 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lineage Cell Therapeutics biotechnology to provide analysis

Correlation between past revenue and Lineage Cell Therapeutics biotechnology search interest

There is not enough data for Lineage Cell Therapeutics biotechnology to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lineage Cell Therapeutics biotechnology to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for LCTX
Earnings date: 2024-03-07 After close
Company name: Lineage Cell Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-12T20:01:00Z

BusinessWire
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-05T12:00:00Z

BusinessWire
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

2026-05-04T12:00:00Z

BusinessWire
OpRegenĀ® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

2026-04-13T12:00:00Z

BusinessWire
Lineage Announces Formation of Scientific Advisory Board

2026-04-10T09:55:00-04:00

PR Newswire
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

2026-04-06T13:10:00-04:00

PR Newswire
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines

2026-03-24T15:19:23Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

2026-03-24T12:00:00Z

BusinessWire
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

2026-03-18T10:00:00-04:00

PR Newswire
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

2026-03-06T18:42:08Z

Analyst Upgrades
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $3

2026-03-05T21:01:00Z

BusinessWire
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

2026-02-26T13:00:00Z

BusinessWire
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

2026-01-29T13:31:00-05:00

PR Newswire
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

2025-12-16T11:53:00-05:00

PR Newswire
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy

2025-11-25T12:58:44Z

Analyst Upgrades
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target